Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • rare diseases

    - PMLiVE

    Havas Life London unveils AI awareness campaign

    The campaign highlights the dangers of AI misinformation in rare disease

    - PMLiVE

    FDA approves first gene therapy for Wiskott-Aldrich syndrome

    Symptoms of the rare disease include bleeding, eczema and frequent infections

    - PMLiVE

    AstraZeneca announces $2bn investment in US manufacturing

    The new and expanded facilities will support production of rare disease drug treatments

    - PMLiVE

    AstraZeneca reports positive results from rare disease trial

    HES is a group of rare disorders characterised by persistently elevated levels of white blood cells

    - PMLiVE

    Havas Life London appoints Fran Griffin as Head of Strategy

    Griffin moves from BBH London to Havas Health

    - PMLiVE

    Amgen’s Uplizna approved by FDA as first treatment for rare disease IgG4-RD

    Immunoglobulin G4-related disease affects approximately 20,000 people in the US

    - PMLiVE

    FDA approves Soleno’s Vykat XR as first treatment for hyperphagia in Prader-Willi syndrome

    The rare genetic disorder affects an estimated one in every 15,000 newborns in the US

    - PMLiVE

    Novartis’ Fabhalta granted FDA approval to treat ultra-rare kidney disease C3G

    Approximately half of C3G patients progress to kidney failure within ten years of diagnosis

    - PMLiVE

    Novartis shares positive phase 3 results for spinal muscular atrophy gene therapy

    The company said it is planning to file regulatory applications for OAV101 IT this year

    - PMLiVE

    NICE recommends Pharming’s Joenja as first treatment for ultra-rare immune disease APDS

    Approximately 40 to 50 people in the UK are known to be living with the inherited disorder

    - PMLiVE

    Amgen’s Uplizna shows promise in phase 3 generalised myasthenia gravis study

    Regulatory submissions are expected to be complete in the first half of this year

    - PMLiVE

    Vertex’s triple combination cystic fibrosis therapy Alyftrek approved by MHRA

    Over 11,000 people in the UK are affected by the rare genetic disease

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links